Financials

News Discussions Technicals Forecast Seasonals

PHIL fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Philogen SpA engages in the engineering and clinical development of lead products capable of targeting angiogenesis. Its products include Nidlegy, Fibromun, Darleukin, Dodekin, Onco IX, Tripokin, OncoFAP, and Dekavil. The company was founded by Dario Neri, Duccio Neri, and Giovanni Neri in 1996 and is headquartered in Siena, Italy.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

PHIL does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company